Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 2/20 | 0.64 |
| ▸ | TNFRSF1A | P19438 | 9/20 | 0.63 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6040819 | 0.88 | TNFRSF1A (0.65) | HDAC2TNFRSF1AF3MAPTMEN1 | |
| SCHEMBL4727774 | 0.88 | TNFRSF1A (0.65) | HDAC2TNFRSF1AF3MAPTMEN1 | |
| SCHEMBL6040823 | 0.88 | TNFRSF1A (0.65) | HDAC2TNFRSF1AF3MAPTMEN1 | |
| SCHEMBL25202047 | 0.88 | TNFRSF1A (0.65) | HDAC2TNFRSF1AF3MAPTMEN1 | |
| SCHEMBL4727769 | 0.88 | TNFRSF1A (0.65) | HDAC2TNFRSF1AF3MAPTMEN1 | |
| SCHEMBL25190515 | 0.88 | TNFRSF1A (0.65) | HDAC2TNFRSF1AF3MAPTMEN1 | |
| SCHEMBL6040629 | 0.86 | TNFRSF1A (0.63) | HDAC2TNFRSF1AF3MAPTMEN1 | |
| SCHEMBL6040624 | 0.86 | TNFRSF1A (0.63) | HDAC2TNFRSF1AF3MAPTMEN1 | |
| SCHEMBL6040804 | 0.82 | TNFRSF1A (0.58) | HDAC2TNFRSF1AF3MAPTMEN1 | |
| SCHEMBL6040810 | 0.82 | TNFRSF1A (0.58) | HDAC2TNFRSF1AF3MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7737283-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737283-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| US-7666895-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666895-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090137021-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2009-05-28 | — | — | US | disclosed |
| US-20090137021-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2009-05-28 | — | — | US | disclosed |
| US-7531566-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531566-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-05-12 | — | — | US | disclosed |
| US-20090105230-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2009-04-23 | — | — | US | disclosed |
| US-20090105230-A1 | Anti-inflammatory medicaments | FLYNN DANIEL L | 2009-04-23 | — | — | US | disclosed |
| US-20080045531-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2008-02-21 | — | — | US | disclosed |
| US-20080045531-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2008-02-21 | — | — | US | disclosed |
| US-7279576-B2 | Anti-cancer medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279576-B2 | Anti-cancer medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-7202257-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202257-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070037808-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-02-15 | — | — | US | disclosed |
| US-20070037808-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105230-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | HDAC2 2007/4885TNFRSF1A 834/4885F3 3422/4885 |
| US-20070037808-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | HDAC2 2088/4885TNFRSF1A 412/4885F3 3301/4885 |
| US-20080045531-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | HDAC2 2007/4885TNFRSF1A 834/4885F3 3422/4885 |
| US-20070191336-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | HDAC2 2088/4885TNFRSF1A 412/4885F3 3301/4885 |
| US-20090137021-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | HDAC2 2007/4885TNFRSF1A 834/4885F3 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.